Home › Research › Clinical trials
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders
Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C et al.. Current Alzheimer research, 2009-04-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery (NTB) and a decrease in brain volume compared with placebo. The results were analyzed by comparing patients originally identified as antibody responders in the AN1792 phase 2a study with placebo-treated patients. Results One hundred and fifty-nine patients/caregivers (30 placebo; 129 AN1792) participated in this follow-up study. Significantly less decline was observed on the Disability Assessment for Dementia scale among antibody responders than placebo-treated patients (p=0.015) after 4.6 years. Significant differences in favor of responders were also observed on the Dependence Scale (p=0.033). Of the small number of patients who underwent a follow-up MRI, antibody responders showed similar brain volume loss during the follow-up period subsequent to the AN1792 phase 2a study compared with placebo-treated patients. Conclusions Approximately 4.6 years after immunization with AN1792, patients defined as responders in the phase 2a study maintained low but detectable, sustained anti-AN1792 antibody titers and demonstrated significantly reduced functional decline compared with placebo-treated patients. Brain volume loss in antibody responders was not significantly different from placebo-treated patients approximately 3.6 years from the end of the original study.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vellas, B., Black, R., Thal, L. J., Fox, N. C., Daniels, M., McLennan, G., et al. (2009). Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Current Alzheimer research. https://doi.org/10.2174/156720509787602852
Vancouver
Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Current Alzheimer research. 2009. doi:10.2174/156720509787602852. PMID: 19355849.
BibTeX
@article{vellas2009-19355849,
author = {Vellas, B. and Black, R. and Thal, L. J. and Fox, N. C. and Daniels, M. and McLennan, G. and Tompkins, C. and Leibman, C. and others},
title = {{Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders}},
journal = {Current Alzheimer research},
year = {2009},
doi = {10.2174/156720509787602852},
pmid = {19355849},
url = {https://doi.org/10.2174/156720509787602852}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery (NTB) and a decrease in brain volume compared with placebo.
- The results were analyzed by comparing patients originally identified as antibody responders in the AN1792 phase 2a study with placebo-treated patients.
- Results One hundred and fifty-nine patients/caregivers (30 placebo; 129 AN1792) participated in this follow-up study.
- Significantly less decline was observed on the Disability Assessment for Dementia scale among antibody responders than placebo-treated patients (p=0.015) after 4.6 years.
- Significant differences in favor of responders were also observed on the Dependence Scale (p=0.033).
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Evidence strengthHigh
How this study scored 66/100
Published in a peer-reviewed journal, and it is a mid-stage phase 2 trial. Scored zero for sample size, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record and institution's track record, so those were left out: it earned 40 of the 61 points we could judge it on, which is 66 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Alzheimer research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 8 / 12 | A mid-stage phase 2 trial (from PubMed type “Clinical Trial, Phase II”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19355849) |
| Free to read | 2 / 2 | Free to read |
| Points | 40 / 61 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 40 of the 61 points we could judge it on is 66 out of 100. |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “long-term-follow-up”
2 studies in the library carry the topic tag “long-term-follow-up”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.